Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflammation and Microbiome in Urgency Urinary Incontinence Treated With Anticholinergics
NCT04090190Phase 4Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of oxybutynin, solifenacin, tolterodine, trospium, fesoterodine in urge incontinence, sponsored by Brigham and Women's Hospital. Started Oct 2019; status: completed.
02
Drugs
oxybutyninsolifenacintolterodinetrospiumfesoterodine
03
Conditions
urge incontinence
Beyond the preview
Go deeper on NCT04090190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090190.